SB 574 Oklahoma Senate · 2026 Regular Session

Attorney General; broadening approved purposes for opioid grant awards; authorizing certain use of funds by the Attorney General. Effective date.

SB 574 expands the types of opioid-related projects eligible for state grant funding by allowing the Attorney General to allocate funds toward new prevention, treatment, and recovery initiatives. It directly affects state agencies and community organizations receiving opioid grants by broadening allowable uses beyond current restrictions. The bill authorizes the Attorney General to use grant funds for specific, previously ineligible activities, such as community-based support programs. This policy change modifies how opioid grant funds are distributed without altering the grant application process.

Bill status vetoed 4 of 5 stages cleared

Introduction

Feb 2025

Committee Review

May 2025

Senate Passage

Mar 2025

House Passage

May 2025

Vetoed

May 2025

Introduced Feb 3, 2025 Vetoed May 29, 2025

Maddy AI version diff · 4 comparisons

What changed between versions

Floor (House) → Floor (Senate) · 4 edits

MODERATE

The bill was amended to transition from a House version to a Senate floor version, incorporating committee amendments that redefine key terms related to opioid abatement grants. The changes clarify definitions for approved purposes, expand the scope of eligible activities, and update statutory references to align with current legislative language.

Scope change

The bill's scope was expanded to include additional approved purposes for opioid abatement grants, such as addressing needs of parents and caregivers of infants with neonatal abstinence syndrome, and supporting efforts to prevent overprescribing of opioids.

DEFINITION

Updated definitions for 'Approved purpose' and 'Nonapproved purpose' to include new categories like addressing needs of pregnant women with opioid use disorder and preventing overprescribing of opioids.

Clarified definition of 'Opioid funds' to exclude all other funds received pursuant to the Purdue Settlement Agreement.

ELIGIBILITY

Added eligibility for grants to address needs of parents and caregivers caring for babies with neonatal abstinence syndrome.

TECHNICAL

Changed document header from 'HOUSE OF REPRESENTATIVES - FLOOR VERSION' to 'SENATE FLOOR VERSION' and updated session information to reflect Senate amendments.

Engrossed → Enrolled (final version) · 7 edits · May 7, 2025

MODERATE

The bill was converted from an Engrossed version to an Enrolled (final) version, with significant substantive changes to the definitions and scope of opioid abatement funding. The most notable changes include the addition of new purposes for approved funding, clarification of what constitutes 'opioid funds' and 'pharmaceutical supply chain participants,' and the removal of certain funding categories while adding others related to law enforcement and legal expenses.

Scope change

The bill's scope was expanded to include new approved purposes for opioid abatement funding, particularly expanding law enforcement and emergency responder support, and clarifying the definition of pharmaceutical supply chain participants to include those involved in manufacturing, marketing, promoting, distributing, or dispensing opioid analgesics.

FISCAL

Added reimbursement for law enforcement and emergency responder expenditures related to the opioid epidemic, including costs for responding to emergency calls, equipment, treatment, and mental health response training.

Added reimbursement for attorney fees and allowable expenses directly related to opioid litigation incurred through legal services agreements entered into before May 21, 2020.

Added new approved purpose to support efforts to prevent or reduce overdose deaths through increased availability and distribution of naloxone and other overdose treatment drugs for first responders, families, schools, and community service providers.

Removed language regarding the Oklahoma Opioid Abatement Board's identification of opioid abatement purposes, replacing it with a broader definition that includes purposes identified by the Board.

DEFINITION

Modified the definition of 'Opioid funds' to specifically include all monetary amounts from opioid litigation involving pharmaceutical supply chain participants, including the Purdue Political Subdivisions Subdivision Fund, while excluding other funds from the Purdue Settlement Agreement.

Added new definition for 'Pharmaceutical supply chain participant' to include any entity that engages in or has engaged in the manufacture, marketing, promotion, distribution, or dispensing of an opioid analgesic.

Modified the definition of 'Opioid grant awards' to clarify that these are grants funded from the Oklahoma Opioid Abatement Revolving Fund awarded pursuant to the Political Subdivisions Opioid Abatement Grants Act.

Floor votes · Senate Mar 24, 2025 · House May 6, 2025

How they voted

41–7

Passed · 1 other

Total votes 49

Mar 24, 2025

D Democratic9

9 Yea

100% Yea

R Republican40

32 Yea 7 Nay 1

80% Yea

Vote distribution

All Yea All Nay Mixed No data

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

May 29, 2025

Introduced

Filed with Secretary of State

upper

May 29, 2025

Vetoed

Veto overridden: Ayes: 72 Nays: 10

lower

May 29, 2025

Vetoed

Veto override message received

lower

May 29, 2025

Vetoed

Veto overridden: Ayes: 33 Nays: 14

upper

May 13, 2025

Vetoed

Vetoed 05/13/2025

upper

May 6, 2025

Committee

Referred for enrollment

upper

May 6, 2025

Lower · Passed

Third Reading, Measure passed: Ayes: 66 Nays: 17

lower

Apr 16, 2025

Lower · Passed

CR; Do Pass Health and Human Services Oversight Committee

lower

Apr 9, 2025

Lower · Passed

Policy recommendation to the Health and Human Services Oversight committee; Do Pass Alcohol, Tobacco and Controlled Substances

lower

Apr 1, 2025

Committee

Referred to Alcohol, Tobacco and Controlled Substances

lower

Mar 25, 2025

Introduced

First Reading

lower

Mar 25, 2025

Upper · Passed

Engrossed to House

upper

Mar 24, 2025

Committee

Referred for engrossment

upper

Mar 24, 2025

Upper · Passed

Measure passed: Ayes: 39 Nays: 7

upper

Mar 24, 2025

Introduced

General Order, Amended

upper

Feb 26, 2025

Upper · Passed

Reported Do Pass as amended Appropriations committee; CR filed

upper

Feb 19, 2025

Committee

Referred to Appropriations

upper

Feb 19, 2025

Upper · Passed

Reported Do Pass as amended Judiciary committee; CR filed

upper

Feb 3, 2025

Introduced

First Reading

upper

2 primary · 0 co-sponsors